Evidence map›Paper›PMID 42051510›Full record

ArticleFrontiers in immunology2026

CXCL2 affects macrophage antitumor function and immunotherapy efficacy in esophageal squamous cell carcinoma through calcium signaling.

Meiying Gu, Zhenkun Liu, Xinlei Zhao, Wei He, Ruifeng Song, Tao Liu, Xiaofeng Liu, Jia Huo, Hongyi Yang, Peng Zhao and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Meiying Gu *Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Zhenkun Liu *Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Xinlei Zhao *Institute for Pathology, University Hospital of Cologne, Cologne, Germany.
Wei HeDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Ruifeng SongDepartment of Gastroenterology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Tao LiuDepartment of Gastrointestinal Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Xiaofeng LiuDepartment of Gastroenterology, Anyang Yindu District Hospital of Traditional Chinese medicine, Anyang, Henan, China.
Jia HuoDepartment of Radiotherapy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Hongyi YangReproductive Medicine Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Peng ZhaoDepartment of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Jialei WengDepartment of Surgical Oncology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Yabing DuDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Macrophages, as a major immune cell population within the tumor microenvironment (TME), play a pivotal role in disease progression and therapeutic outcomes. This study aimed to identify key macrophage subsets associated with ESCC immunotherapy response. Methods: Macrophage-specific marker gene associated with immunotherapy response was identified through single-cell RNA sequencing (scRNA-seq) analysis. The clinical relevance of CXCL2 Results: ScRNA-seq analysis showed that CXCL2 was predominantly expressed in macrophages within TME and significantly upregulated in immunotherapy-responsive ESCC patients. Low infiltration of intratumoral CXCL2 Conclusion: Macrophage-specific CXCL2 represents a novel biomarker for predicting immunotherapy efficacy and may potentiate the efficacy of anti-PD-1 therapy in ESCC patients.

Indexed as

Calcium SignalingChemokine CXCL2Esophageal NeoplasmsEsophageal Squamous Cell CarcinomaMacrophagesAnimalsBiomarkers, TumorCell Line, TumorFemaleHumansImmunotherapyMaleMiceTumor-Associated MacrophagesTumor MicroenvironmentBiomarkers, TumorChemokine CXCL2CXCL2 protein, humancalcium signalingCXCl2ESCC immunotherapymacrophagestumor microenvironment

Identifiers

PMID42051510
PMCPMC13111272

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.